Portal Vein Embolization Prior to Major Hepatic Resection
Portal vein embolization (PVE) should be performed in patients requiring extensive liver resection when the future liver remnant (FLR) is less than 20% in normal liver, less than 30-35% in mild liver disease, or less than 40% in severe steatosis or cirrhosis. 1
Indications for PVE
PVE is the most widely used volume optimization strategy and is indicated for patients requiring extensive liver resection (≥5 segments) with borderline or insufficient FLR volume 1. The specific thresholds are:
- Normal liver: FLR < 20%
- Mild steatosis, cholestasis, or early cirrhosis (Child-Pugh A): FLR < 30-35%
- Severe steatosis or cholestasis: FLR < 40%
- Cirrhosis with fibrosis: FLR < 40-50% 1
Additional functional assessment using indocyanine green (ICG) clearance test can guide decision-making, with ICGR15 > 15-20% indicating impaired hepatic reserve and need for volume optimization 1.
Technical Approach
Access Routes
The portal venous system is accessed through a percutaneous trans-hepatic approach, with two options 1:
Ipsilateral approach (portal access on the same side being resected) with retrograde embolization
- Advantages: Minimizes risk of injury to FLR; allows easy catheterization of segment 4 branches in right-sided tumors
- Preferred for most cases
Contralateral approach (portal access through FLR) with antegrade embolization
- Safe technique with low complication rate (6% complications, with only 3% related to access route and none precluding resection) 1
Embolic Materials
Multiple agents have similar efficacy, including glue, Gelfoam, n-butyl-cyanoacrylate (NBC), various beads, alcohol, and nitinol plugs 1. The choice depends on operator preference and access route—some materials (e.g., glue) are difficult to manipulate from the ipsilateral side, while large embolic agents require larger diameter needles 1.
Important caveat: For extended right hepatectomy, consider segment 4 embolization to maximize FLR hypertrophy 1.
Timing and Expected Outcomes
Hypertrophy Timeline
- Rapid growth phase: First 3-4 weeks post-PVE
- Continued growth: Up to 8 weeks 1
- Expected FLR increase: 40-62% after median of 34-37 days 1
- Technical success: Over 90% feasibility 1
- Resection completion rate: Up to 80% of patients proceed to planned resection 1
Optimal Timing for Resection
Perform hepatectomy 4-6 weeks after PVE once adequate FLR growth is demonstrated 1. Waiting longer than 6 weeks may increase risk of tumor progression during the waiting period 1.
Critical point: Neoadjuvant chemotherapy does not appear to impact the rate of FLR hypertrophy 1.
Follow-up Imaging and Decision Criteria
Volumetric Assessment
Reimaging should be performed at 4-6 weeks post-PVE using CT or MRI with volumetric analysis 1. Calculate:
- Total liver volume (TLV)
- FLR volume
- Tumor volume (TV)
- Functional liver volume (FLV) = TLV - TV 1
Minimum Hypertrophy Criteria for Proceeding to Resection
The degree of FLR hypertrophy is an important prognostic factor and helps identify patients at high risk of post-hepatectomy liver failure (PHLF) 1:
- Normal liver: Minimum 5% FLR hypertrophy
- Severe underlying liver disease (fibrosis/cirrhosis): Minimum 10% FLR hypertrophy 1
Patients with ≤5% FLR hypertrophy after embolization have significantly higher risk of PHLF and should be considered relative contraindications for resection 1.
Safety and Complications
PVE carries low risk of complications comparable to percutaneous liver biopsy 2. The procedure is:
- Technically feasible: >90% of patients 1
- Well tolerated: Minimal biological impact in patients without liver failure 2
- Safe in cirrhosis: Well tolerated in selected Child-Pugh A cirrhotic patients without significant portal hypertension 1
Special Considerations in Cirrhosis
For hepatocellular carcinoma patients with cirrhosis, combining transcatheter arterial chemoembolization (TACE) with PVE results in increased hypertrophy rate (12% vs 8%, p=0.022) and better disease-free and overall survival compared to PVE alone 1, 3.
Clinical Outcomes
Patients with borderline FLR who undergo hepatectomy after PVE show superior outcomes compared to those resected without PVE, including 1:
- Significantly lower PHLF incidence (2.5%)
- Lower perioperative mortality (0.8%)
- Reduced post-operative complications
- Shorter ICU and hospital stays
However, no benefit of PVE is seen in patients with normal liver and FLR > 30% 1.